Breast Cancer

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Tamoxifen is given to many patients—specifically premenopausal patients—with breast cancers that express the estrogen receptor, which drives breast tumor growth.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.

Further, among premenopausal women, those who received chemotherapy had a 40% relative improvement in IDFS compared to those administered endocrine therapy alone.

The diagnostic tool widens the age group of individuals who can get tested and can be used in conjunction with a mammogram.

Olaparib was the first PARP inhibitor to be developed and has been the most studied.

Breast cancer found to be the most expensive type of the disease, costing approximately $3.4 billion in the United States.

Atrial fibrillation was more common in those not treated with radiation (66.5%) or surgery (23.5%) as first-line treatment compared with 52.3% and 10.4%, respectively.

Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Study results show no differences in the rate of neuropathic pain, surgical site infection, wound-related complications, or other complications between the 2 groups.

Ten quiz questions to assess your knowledge on common symptoms and treatments for breast cancer.

TNBC is the most aggressive and lethal form of the disease.

Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.

The study was designed to evaluate elacestrant as a monotherapy compared to the standard of care for the treatment of estrogen receptor-positive/human epidermal growth factor receptor 2 advanced or metastatic breast cancer.

Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.

Investigators conclude that minimal residual disease cells, or those that survive the initial treatment, may carry some form of epigenetic and metabolic memory of the tumor.

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.

There is a survival advantage for those who were also treated with surgery, according to new study results.

They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

Allostatic load is caused by a number of different stressors, including social isolation, poverty, and racism, many of which are commonly experienced by individuals belonging to racial and ethnic minorities, according to the investigators.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

The investigators said these results suggest patients with low sTK1 activity levels have slow-growing disease, which can be initially controlled through single-drug endocrine therapy.